Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia by Campian, Maria E. et al.
ORIGINAL ARTICLE
Assessment of inflammation in patients with arrhythmogenic
right ventricular cardiomyopathy/dysplasia
Maria E. Campian & Hein J. Verberne & Maxim Hardziyenka &
Elisabeth A. A. de Groot & Astrid F. van Moerkerken & Berthe L. F. van Eck-Smit &
Hanno L. Tan
Received: 12 April 2010 /Accepted: 3 June 2010 /Published online: 6 July 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose Arrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D) is a myocardial disease that predomi-
nantly affects the right ventricle (RV). Its hallmark feature is
fibro-fatty replacement of RV myocardium. However, patchy
inflammatory infiltrates in the RV are also consistently
reported using autopsy and myocardial biopsy. Although the
role of inflammation in ARVC/D is unresolved, the ability to
assess inflammation non-invasively may aid in the diagnostic
process. We aimed to establish whether cardiac inflammation
can be assessed non-invasively in ARVC/D patients.
Methods In eight ARVC/D patients and nine controls
(haematology/oncology patients), the level of inflammatory
activation was assessed by measuring plasma levels of
inflammatory cytokines. Regional myocardial inflammation
was assessed with
67Ga scintigraphy.
Results ARVC/D patients had higher plasma levels than
controls of the pro-inflammatory cytokines interleukin (IL)-
1β (1.22±0.07 vs 0.08±0.01 pg/ml, p<0.0001), IL-6 (3.16±
0.44 vs 0.38±0.04 pg/ml, p<0.0001) and tumour necrosis
factor (TNF)-α (9.16±0.90 vs 0.40±0.06 pg/ml, p<0.0001),
while levels of the anti-inflammatory cytokine IL-10 were
not significantly different (1.36±0.15 vs 1.20±0.30 pg/ml,
p=0.74).
67Ga uptake in the RV was higher in ARVC/D
patients than in controls. In ARVC/D patients,
67Ga uptake
in the RV wall was higher than in the interventricular septum
or left ventricular wall.
Conclusion Inflammation in the RV wall of ARVC/D
patients can be detected non-invasively with the combined
analysis of plasma levels of inflammatory cytokines and
cardiac
67Ga scintigraphy.
Keywords Arrhythmogenic right ventricular
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Abbreviations
ARVC/D Arrhythmogenic right ventricular
cardiomyopathy/dysplasia
IL-1β Interleukin 1 beta
IL-6 Interleukin 6
IL-10 Interleukin 10
IVS Interventricular septum
LV Left ventricle/ventricular
ROI Region of interest
RV Right ventricle/ventricular
TNF-α Tumour necrosis factor alpha
Introduction
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is a myocardial disease that predominantly
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DOI 10.1007/s00259-010-1525-yaffects the right ventricle (RV), although biventricular
involvement may occur in advanced cases [1]. ARVC/D is
characterized by structural derangements that may cause a
broad range of signs and symptoms. Yet, disease expression
is highly variable and incomplete in most patients,
confounding both the diagnostic process and clinical
management, particularly at early disease stages [2].
The histopathological hallmark of ARVC/D is fibro-
fatty replacement of RV myocardium [3]. Nevertheless,
patchy inflammatory infiltrates in the RV are also
consistently reported [3, 4]. How fibro-fatty replacement
and inflammatory infiltrates are related is a matter of
speculation.
It has been proposed that the progressive loss of RV
myocardium is caused by an inflammatory injury and that
subsequent fibro-fatty replacement is part of a healing
process [3–5].
At present, detection of myocardial inflammation
requires the use of endomyocardial biopsies or analysis of
autopsy material. Although sampling of endomyocardial
biopsies is relatively safe, particularly when guided by
electroanatomical mapping [6], the availability of non-
invasive diagnostic tools would provide obvious advan-
tages for clinical practice. Thus far, the pro-inflammatory
cytokines [interleukin-1β (IL-1β), interleukin-6 (IL-6) and
tumour necrosis factor-α (TNF-α)] have been shown to be
activated and to play a role in chamber dysfunction in
patients with left ventricular (LV) heart failure [7, 8]. Yet, in
ARVC/D, there are no data on possible activation and
detection of the pro-inflammatory cytokines. Although the
pro-inflammatory cytokines are possibly sensitive markers
for disease state, the interpretation is hampered by the lack
of organ-specific identification. In addition to systemic
evaluation, localization of disease to the myocardium is
essential. Previously, we have shown that activation of
inflammatory infiltrates in the ventricular myocardium can
be non-invasively detected with the use of
67Ga scintigra-
phy [9]. Therefore, the aim of the present study was to test
whether inflammation in ARVC/D may be monitored non-
invasively with the complementary use of plasma inflam-
matory cytokine analysis and cardiac
67Ga scintigraphy.
Materials and methods
Patients and control subjects
The Institutional Review Board approved the study
protocol and informed consent was obtained from all
study subjects. Eight ARVC/D patients and nine controls
were examined. All patients were diagnosed with the use
of the ARVC/D Task Force criteria [10]a n dw e r e
randomly taken from the cohort of ARVC/D patients at
our institution, a tertiary referral centre. Patients were
included if they were in clinically stable condition (no
ventricular tachyarrhythmias or heart failure symptoms in
the 2 months before inclusion). Genetic analysis for
plakophilin 2 (PKP2), desmoplakin (DSP), desmoglein 2
(DSG2), desmocollin 2 (DSC2), plakoglobin (JUP) and
transmembrane protein 43 (TMEM43) was conducted in
all patients or the probands in their family [11, 12].
Controls were retrospectively taken from our institution’s
haematological/oncological database and were individuals
in whom
67Ga scintigraphy was routinely performed in
their diagnostic work-up. Their primary disease locus was
extrathoracic, and the acquisition was made before any
form of chemotherapy or radiotherapy. Neither ARVC/D
patients nor controls had a history of coronary artery
disease, diabetes or hypertension.
Plasma level of inflammatory cytokines
We analysed plasma levels of pro-inflammatory cytokines
(IL-1β, IL-6, TNF-α) and the anti-inflammatory cytokine
interleukin-10 (IL-10) using commercially available ultra-
sensitive enzyme-linked immunosorbent assay (ELISA) kits
for human IL-1β, IL-6, TNF-α and IL-10 according to the
manufacturer’s recommendations (Bio-Rad Laboratories,
Hercules, CA, USA). The 95% confidence interval of the
in-hospital reference values obtained in 62 healthy volun-
teers were for IL-1β: 0.0018–0.2118 pg/ml, for IL-6:
0.0895–1.2238 pg/ml, for TNF-α: 0.0212–2.2556 pg/ml
and for IL-10: 0.0483–16.7000 pg/ml.
67Ga scintigraphy
SPECT of the thorax was performed 48 h after an
intravenous injection of 200 MBq of
67Ga-citrate by use
of a gamma camera (Infinia, General Electric, Milwaukee,
WI, USA) with a medium energy all purpose collimator and
a 128×128 matrix. Fifteen perc ent windows were set for
the three main energy peaks of
67Ga (93, 184 and 296 keV).
SPECT images were iteratively reconstructed (ordered
subset expectation maximization,OSEM) and corrected for
attenuation using the low-dose CT of the Infinia (no
intravenous contrast). To define the anatomical borders of
the myocardium within the thorax, anatomical tomographic
images are essential and the low-dose CT images of the
Infinia could not be used for this purpose. Therefore,
tomographic anatomical images (contrast-enhanced CT or
cardiac MRI), performed prior to implantable cardioverter-
defibrillator (ICD) implantation (within 6 months of
67Ga
scintigraphy), were retrieved for all subjects. To align the
anatomical images with the SPECT data, first the matrix
size of the anatomical images was adjusted to the SPECT
matrix size (128×128) and secondly the images were
2080 Eur J Nucl Med Mol Imaging (2010) 37:2079–2085automatically aligned (MultiModality, HERMES Medical
Solutions, Stockholm, Sweden). To semi-quantify
67Ga
myocardial uptake, three regions of interest (ROI) [RV
wall, interventricular septum (IVS) and LV free wall] were
drawn on three summed mid-myocardial horizontal long
axis anatomical images. These ROIs on the anatomical
images were copied to the aligned SPECT images.
67Ga
uptake in each separate ROI was calculated as the ratio of
mean counts per pixel in the specific myocardial region
over mean counts per pixel in the total myocardium (the
sum of all three ROIs).
Statistical analysis
Data are presented as mean±SD. Mean values were
compared for differences using the (un)paired Student’s t
test when appropriate. In cases of multiple comparisons,
means were compared for differences with analysis of
variance (two-way ANOVA) using a post hoc Bonferroni
correction. The correlation coefficient was used to study
possible associations between plasma levels of inflamma-
tory cytokines and myocardial
67Ga uptake (SPSS for
Windows 15.1, SPSS Inc., Chicago, IL, USA). A p value<
0.05 was considered to indicate statistical significance.
Results
Patient characteristics
Table 1 summarizes the demographic/clinical data and the
presence/absence of the ARVC/D criteria in the ARVC/D
patients. All ARVC/D patients fulfilled the ARVC/D Task
Force criteria [13]. Their mean age was 36.8±13.3 years
(range: 20–55 years) and 62.5% (n=5) were female. One
patient had the C796R mutation in PKP2, while one had
the V158G mutation in DSG2. Both variants were
previously reported as ARVC/D-causing mutations [11,
14]. There were no clinical signs of heart failure and
echocardiography revealed normal LV function (not
shown). The mean age of controls was 55.4±11.9 and
22.2% (n=2) were female.
Plasma levels of inflammatory cytokines
The ARVC/D patients had higher plasma levels than
controls of the pro-inflammatory cytokines IL-1β (1.22±
0.07 vs 0.08±0.01 pg/ml, p<0.0001), IL-6 (3.16±0.44 vs
0.38±0.04 pg/ml, p<0.0001) and TNF-α (9.16±0.90 vs
0.40±0.06 pg/ml, p<0.0001). The levels of the anti-
inflammatory cytokine IL-10 were statistically not signifi-
cantly different between both groups (1.36±0.15 vs 1.20±
0.30 pg/ml, p=0.72) (Fig. 1).
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67Ga uptake
Figure 2 shows a typical example of an ARVC/D patient
with increased
67Ga uptake in the RV wall. ARVC/D
patients had significantly higher uptake of
67Ga in the RV
wall and IVS than in the LV wall (1.11±0.08, 1.04±0.06
and 0.89±0.06, respectively, Fig. 3a). In controls, no
differences between these regions were observed (0.97±
0.11, 1.04±0.05 and 0.99±0.04, respectively, Fig. 3b).
Moreover,
67Ga uptake in the RV wall was significantly
higher in ARVC/D patients than in controls (1.11±0.08 vs
0.97±0.11, p=0.01), while
67Ga uptake was not different
between both groups in the IVS (1.04±0.06 vs 1.04±0.05,
p=0.90) and LV wall (0.89±0.06 vs 0.99±0.04, p=0.06).
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Fig. 1 Plasma concentrations of cytokines in ARVC/D patients and controls. IL-1β interleukin-1 beta, IL-6 interleukin-6, IL-10 interleukin-10,
TNF-α tumour necrosis factor alpha
Fig. 2 ARVC/D patient with
increased
67Ga uptake in the RV
wall. Coregistered transaxial
images of cardiac magnetic
resonance imaging (left) and
67Ga SPECT scintigraphy
(right). There is increased
67Ga
uptake in the right ventricular
(RV) wall. IVS interventricular
septum, LV left ventricular free
wall
2082 Eur J Nucl Med Mol Imaging (2010) 37:2079–2085Correlations between plasma levels of inflammatory
cytokines and myocardial
67Ga uptake
Plasma levels of IL-1β and
67Ga uptake in the RV
appeared to correlate positively, but this correlation did
not reach statistical significance (r=0.62, p=0.1). No
correlations were found between plasma levels of IL-6,
TNF-α or IL-10 and the
67Ga uptake in the RV wall.
Similarly, no correlations were found between plasma
levels of IL-6, TNF-α or IL-10 and
67Ga uptake in the LV
wall or IVS.
Discussion
With a combined analysis of plasma level of inflammatory
cytokines and cardiac
67Ga scintigraphy, we demonstrate
that myocardial inflammation can be non-invasively
detected in ARVC/D patients.
The pathophysiology behind the loss of RV myocar-
dium in ARVC/D is unresolved. A common finding is
patchy cell death with inflammatory infiltration [15]. This
has spawned the proposal that ARVC/D has an infectious/
inflammatory aetiology, involving a primary chronic
myocarditis that evokes an inflammatory injury and
culminates in fibro-fatty repair and progressive loss of
RV myocardium. Different types of cardiotropic viruses
may play a role in the pathophysiology of ARVC/D. A
genetic predisposition may lead to increased viral suscep-
tibility and myocarditis [16].
One explanation for the presence of pro-inflammatory
cytokines in ARVC/D is the “cytokine hypothesis” of heart
failure, which proposes that a precipitating event triggers
innate stress response [17]. These cytokines are believed to
be produced by nucleated cells in the heart and subse-
quently released into the bloodstream [18]. In patients with
LV heart failure, pro-inflammatory cytokines contribute, by
various mechanisms, to the deterioration of cardiovascular
function [7, 8, 17]. Furthermore, various cytokines, includ-
ing TNF-α, IL-2, interferon-γ and IL-1β-converting en-
zyme, are increased in viral myocarditis [19]. In ARVC/D,
no data on a possible association between pro-inflammatory
cytokines and disease are available.
Inflammatory mediators such as TNF-α and IL-1β,
known to be elevated in viral myocarditis, can stimulate
the expression of inducible nitric oxide synthase (iNOS)
[20]. Induction of iNOS leads to strand breaks, p53
accumulation and apoptosis, and these processes were
a
b
Fig. 3 Myocardial
67Ga uptake
in ARVC/D patients and con-
trols. Semi-quantitative myocar-
dial
67Ga uptake in ARVC/D
subjects (a) and controls (b).
67Ga uptake in the RV wall,
interventricular septum (IVS)o r
LV wall was calculated as the
ratio of uptake (mean counts per
pixel) in this myocardial region
over the uptake in the total
myocardium (i.e., the sum of all
three ROIs)
Eur J Nucl Med Mol Imaging (2010) 37:2079–2085 2083prevented by iNOS inhibition [21]. Apoptosis, in turn,
evokes an inflammatory response.
The inflammatory response in ARVC/D may not only be
an initial response to a noxious trigger (e.g. viral infection),
but it may also be enhanced because of apoptosis induced
by pro-inflammatory cytokines. Our findings (increased
plasma levels of pro-inflammatory cytokines and
67Ga
uptake in the RV wall) did not allow us to distinguish
whether they indicated an initial response to infection or a
secondary inflammatory response induced by apoptosis.
Moreover, to determine whether inflammation is a viral-
related inflammation or a post-apoptosis inflammatory
reaction, it is essential to perform endomyocardial biopsies.
Although pro-inflammatory cytokines may be sensitive
disease markers, they cannot localize the disease to a
specific organ. Previously, we reported that
67Ga scintig-
raphy can be used to map inflammation non-invasively in
the ventricular myocardium [9]. Although
67Ga scintigra-
phy has a high sensitivity, a major disadvantage of
67Ga
scintigraphy is its limited specificity [22, 27]. In recent
years,
18F-fluorodeoxyglucose positron emission tomog-
raphy (
18F-FDG PET) has emerged as an alternative and
superior method to assess inflammation. However, one of
the preferred substrates of myocardial metabolism is
glucose. This limits the use of
18F-FDG for the detection
of localized myocardial inflammation. Therefore,
67Ga
scintigraphy is most likely to be superior to
18F-FDG for
the detection of myocardial muscle inflammation, despite
its limited specificity.
67Ga thus marks areas of inflamma-
tion (e.g. an infection site) and rapid cell division,
allowing sites with tumour, inflammation, and both acute
and chronic infection to be visualized with scintigraphic
techniques [23–26]. Controversial data were reported in
cases of inflammatory foci in myocarditis.
Study limitations and clinical usefulness
Firstly, a limitation of our study is the small number of
patients. The finding that the correlations between plasma
levels of pro-inflammatory cytokines and myocardial
uptake of
67Ga in the RV wall failed to reach statistical
significance probably relates to this limited number. Still,
the results were highly consistent, as both plasma levels of
pro-inflammatory cytokines and myocardial
67Ga uptake in
the RV wall were increased in ARVC/D patients. Secondly,
it was recently suggested that ARVC/D and myocarditis
cannot be distinguished with the use of currently estab-
lished clinical criteria and that a distinction requires
analysis of biopsy specimens [6]. Although we conducted
no cardiac biopsies, we obtained support for the notion that
we studied patients with ARVC/D, rather than myocarditis,
by including six patients (patients 1, 2, 3, 4, 6 and 7) who
had first-degree relatives that also fulfilled established
criteria for ARVC/D and one other patient (patient 5) with
a mutation that was previously reported to be associated
with ARVC/D.
Conclusion
Inflammation may contribute to disease progression in
ARVC/D and can be assessed non-invasively with the
combined analysis of plasma inflammatory cytokine levels
and cardiac
67Ga scintigraphy. The ability to detect
inflammation non-invasively provides us with a tool that
may be used to obtain a better understanding of the role of
inflammation in the pathophysiology of ARVC/D as it does
in other diseases [27, 28]. The clinical implications of these
findings remain to be assessed in future studies.
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